Logo

IINN

Inspira Technologies Oxy B.H.N. Ltd.

IINN

Inspira Technologies Oxy B.H.N. Ltd. • NASDAQ
$1.08 ▲ 5.63% (+0.06)
Market Cap $26.13 M
52w High $1.65
52w Low $0.40
Dividend Yield 0%
P/E -2.26
Volume 120.17K
Outstanding Shares 24.08M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2023 $0 $3.152M ▲ $-3.008M ▼ 0% $-0.19 ▲ $-3.128M ▼
Q3-2023 $0 $2.642M ▼ $-2.423M ▲ 0% $-0.21 ▲ $-2.408M ▲
Q2-2023 $0 $3.048M ▼ $-2.824M ▼ 0% $-0.24 ▼ $-2.667M ▲
Q1-2023 $0 ▲ $3.287M ▲ $-2.663M ▲ 0% ▼ $-0.23 ▲ $-2.904M ▲
Q4-2022 $-4.678M $3.157M $-3.099M 66.246% $-0.28 $-3.118M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $5.779M ▲ $8.07M ▼ $3.748M ▼ $4.322M ▼
Q2-2024 $3.55M ▼ $9.422M ▲ $4.079M ▲ $5.343M ▼
Q4-2023 $7.361M ▲ $9.31M ▲ $3.572M ▲ $5.738M ▲
Q3-2023 $6.388M ▼ $8.163M ▼ $2.994M ▼ $5.169M ▼
Q2-2023 $8.967M $10.84M $3.288M $7.552M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2023 $-3.008K ▼ $0 $0 $0 $0 ▼ $0
Q3-2023 $-2.423K ▲ $0 ▼ $0 $0 $3K ▲ $0 ▼
Q2-2023 $-2.824K ▲ $1.017K ▲ $0 $0 $-3.038M ▼ $1.017K ▲
Q1-2023 $-3.031K ▲ $0 ▲ $0 ▲ $0 ▲ $-477K ▼ $0 ▲
Q4-2022 $-7.831K $-1.472M $-7.197M $-11.243M $652K $-1.644M

Five-Year Company Overview

Income Statement

Income Statement Inspira is still a pre‑revenue company: it has not yet generated meaningful sales from its devices. Its income statement is driven mainly by research, development, and corporate expenses, which leads to ongoing losses. Those losses have moderated a bit over time but remain material relative to the company’s very small size. The path to healthier results depends almost entirely on moving from development into commercial sales and doing so at enough scale to cover fixed operating costs.

Balance Sheet

Balance Sheet The balance sheet is light and simple. Assets are modest, with cash as the main component, and there is essentially no financial debt, which reduces interest burden but also reflects limited borrowing capacity. Equity is thin, which means there is not a large cushion to absorb ongoing losses. Continued operations are likely to depend on raising additional capital or quickly converting the product pipeline into revenue.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, which is typical for an early‑stage medical device company that is investing in R&D and regulatory work without yet having product sales. Capital spending is minimal, so the main cash use is operating expenses. This pattern points to a business that is still in the build‑out phase and reliant on external funding to support its cash burn until commercialization gains traction.

Competitive Edge

Competitive Edge Inspira is trying to carve out a niche in respiratory support by offering less invasive alternatives to traditional mechanical ventilation and standard ECMO systems. Its focus on “awake” and lower‑flow oxygenation aims at patients who are not well served by existing options, which could open a new treatment category. The company’s patent portfolio and long‑dated protection around its core VORTX and ART technologies help build a technological moat. That said, it operates in a market dominated by large, well‑funded medical device players, and it must overcome high regulatory, clinical, and hospital‑adoption hurdles to secure a durable position.

Innovation and R&D

Innovation and R&D Innovation is the clear heart of Inspira’s story. The company is developing a family of products: an initial ART system already cleared for certain heart‑lung procedures, a next‑generation ART500 system aimed at conscious patients, a HYLA continuous blood‑monitoring sensor, and a portable Cardi‑ART device for cardiac arrest support. These technologies are protected by multiple patents and are designed to reduce complications versus traditional methods. However, they still need to pass through further clinical validation, regulatory approvals, and real‑world adoption tests, so execution risk around R&D, trials, and timelines remains high.

Summary

Inspira is an early‑stage, highly innovative medical device company with no meaningful revenue yet, ongoing losses, and a small but debt‑free balance sheet. Its value proposition centers on novel respiratory and cardiac support technologies that could change how certain critically ill patients are treated. Strong intellectual property and a differentiated product pipeline are key strengths, while the lack of commercial scale, continuing cash burn, and intense competition from larger incumbents are key risks. The story going forward will hinge on regulatory approvals, hospital adoption, and the company’s ability to finance itself through the transition from development to commercialization.

NEWS

November 13, 2025 · 9:00 AM UTC

Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission

Read more

November 6, 2025 · 9:10 AM UTC

Inspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion

Read more

October 22, 2025 · 8:30 AM UTC

Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira's Global Ecosystem

Read more

October 21, 2025 · 9:05 AM UTC

Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm

Read more

October 1, 2025 · 8:00 AM UTC

Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

Read more